EGFR and colorectal cancer: For example, the epidermal growth factor receptor- (EGFR-) targeted agent cetuximab was initially developed for colorectal cancers overexpressing EGFR, but subsequent analyses have demonstrated that KRAS wild-type and NRAS wild-type status identify those tumors that are most sensitive to cetuximab [5], resulting in a new standard molecular profiling test to guide treatment selection.